Expansion of domestic Phase 3 clinical trial sites for achondroplasia treatment Umepaptanib pegol to 16 sites nationwide (cumulative 10 sites currently, plan to 16); no impact on fiscal year 2027 performance. Subjects are pediatric patients with rare diseases; new IRB-approved sites expanding.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"\u682a\u5f0f\u4f1a\u793e\u4f1a\u30ea\u30dc\u30df\u30c3\u30af","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4591-20260803-01.pdf","jir_short_summary":"Expansion of domestic Phase 3 clinical trial sites for achondroplasia treatment Umepaptanib pegol to 16 sites nationwide (cumulative 10 sites currently, plan to 16); no impact on fiscal year 2027 performance. Subjects are pediatric patients with rare diseases; new IRB-approved sites expanding.","jir_summary":"### Overview of performance and trial expansion\nThis news item reports the expansion of implementing medical institutions for domestic Phase 3 clinical trials of the achondroplasia treatment Umepaptanib pegol. Four new sites have obtained Institutional Review Board approvals, bringing the total implementing sites to 10. The plan is to expand nationwide to 16 sites, strengthening the trial framework in the rare disease area.\n\n### Outlook and impact on investors\nExpansion of trial sites is expected to accelerate subject enrollment and strengthen nationwide trial operations; however, the impact on the full-year results for the fiscal year ending March 2027 is currently unchanged, with limited short-term financial effects. Development in the rare disease space may contribute to long-term value creation.","jir_financial_highlights":"Impact: Unknown (Unknown)","jir_category":"","jir_hashtags":"#\u682a\u5f0f\u4f1a\u793e\u4f1a\u30ea\u30dc\u30df\u30c3\u30af, #IR, #\u65e5\u672c\u682a","jir_key_figures":"Cumulative implementing sites: 10\u219216 planned (expansion)\nPoint in time of expansion: IRB approval already obtained for trial sites\nImpact on FY2027 results: None","jir_meta_title":"\u3010\u682a\u5f0f\u4f1a\u793e\u4f1a\u30ea\u30dc\u30df\u30c3\u30af\u3011Domestic Phase III trial site expansion announcement\uff5cAugust 2026","jir_meta_description":"Rebymick expands domestic Phase III trial sites for Umepaptanib pegol nationwide. Expansion from 10 to 16 facilities planned. No impact on FY2027.","jir_og_title":"\u3010\u682a\u5f0f\u4f1a\u793e\u4f1a\u30ea\u30dc\u30df\u30c3\u30af\u3011Trial site expansion announcement","jir_og_description":"Expansion of domestic Phase III trial sites for achondroplasia treatment nationwide. No financial impact for FY2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-93458","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n